CSIR-IMTech Signs MOU with Johnson & Johnson for collaborative research on TB
CSIR-IMTech has entered into a new collaboration with global pharmaceutical company, Johnson and Johnson for development of new drugs for treatment of tuberculosis (TB). The Johnson and Johnson have recently developed a “Bedaquiline” for treatment of drug-resistant TB and has been approved by several countries of world including US, Europe and India. To further engage in next-generation of TB drug discovery, a Memorandum of Understanding (MoU) has been signed between IMTECH and Johnson & Johnson for collaborative research on TB.
CSIR-IMTECH also organized a mini-conference, ‘Dr Paul Janssen TB Symposium’ on 17th August, 2017 in memory of late Dr Paul Janssen who one of the most influential scientist of 20th century and is credited with discovery of more than 80 medicines, some of which are on WHOs list of essential medicines. His vision and mission of discovering drugs for diseases including TB, has helped millions of patients across the world.
The mini-symposium was dedicated to address the issues related to TB drug development &public health policy and potential of public private partnership for drug discovery in neglected diseases. This symposium also endeavored to reinforce the vision laid out by late Dr Paul Janssen to address the unmet medical needs of poorest of poor.
The symposium was graced by Dr Paul Stoffels, Chief Scientific Officer of Johnson &Johnson who delivered a key note address on this occasion.